- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Fr | Roche's Tecentriq combo scores in first-line melanoma | ||
| Fr | House Democrats finally pass landmark drug pricing bill | ||
| Fr | UPDATED: Senate officially confirms Stephen Hahn as FDA commissioner | ||
| Fr | FDA grants surprise OK to Sarepta's DMD therapy after earlier rejection | ||
| Fr | Brexit nears as Conservatives sweep to victory in election | ||
| Do | New faces at JPA Health Communications, GCI Health and HRW | ||
| Do | PharmaLex announces joint venture with Vintura | ||
| Do | Biologic patent exclusivity scrapped in new US trade deal | ||
| Do | AZ, Daiichi Sankyo strengthen case for HER2 candidate | ||
| Do | UCB/Amgen's Evenity finally cleared for osteoporosis in Europe | ||
| Do | Intec battered as Novartis ducks out of Accordion collaboration | ||
| Do | J&J appeals Oklahoma opioid verdict, claiming 'errors' in trial | ||
| Mi | Correvio crumbles as FDA panel rejects AFib drug | ||
| Mi | BMS' oral maintenance therapy boosts survival in AML patients | ||
| Mi | Sanofi's sutimlimab set for filing in rare autoimmune anaemia next year | ||
| Mi | Sanofi narrows focus, shedding diabetes and cardiovascular research | ||
| Mi | Pharma Brand Planners' Blog (Part 7) | ||
| Di | J&J and Bristol-Myers Squibb/Bluebird bio reveal rival CAR-T data | ||
| Di | Regeneron reveals first data for bispecific antibody in multiple myeloma | ||
| Di | Merck buys ArQule for $2.7bn in another cancer bolt-on deal | ||
| Di | J&J splashes $750m on anti-inflammatory drug bermekimab | ||
| Di | Healthcare trends 2020 - the biggest shifts changing lives and life sciences | ||
| Di | Sanofi's new CEO cuts first deal, adding Synthorx for $2.5bn | ||
| Mo | Bluebird bio's sickle cell gene therapy shows early-study benefit | ||
| Mo | AstraZeneca's Calquence impresses in previously untreated CLL |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
